Nifty
:
21995.85
Sensex
:
72488.99
-152.05 (-0.69%)
-454.69 (-0.62%)
Nifty
Sensex
:
:
21995.85
72488.99
-152.05 (-0.69%)
-454.69 (-0.62%)

Dr. Reddy's Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
53/99

BSE: 500124 | NSE: DRREDDY

NSE BSE
5957.15
18-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  6099.95
  •  6127.50
  •  5937.65
  •  6050.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  597736
  •  36125.00
  •  6505.90
  •  4384.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 99,408.67
  • 19.01
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 97,445.87
  • 0.67%
  • 3.70

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.65%
  • 0.49%
  • 8.44%
  • FII
  • DII
  • Others
  • 28.62%
  • 16.16%
  • 19.64%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.28
  • 9.81
  • 9.00

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.92
  • 14.84
  • 10.41

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.67
  • 18.78
  • 33.28

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.37
  • 25.23
  • 23.62

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.78
  • 3.92
  • 3.88

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.87
  • 16.71
  • 15.07

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
7,236.80
6,789.80
6.58%
6,902.60
6,331.80
9.01%
6,757.90
5,232.90
29.14%
6,315.20
5,474.90
15.35%
Expenses
5,213.70
4,851.30
7.47%
4,894.30
4,432.90
10.41%
4,695.80
4,291.70
9.42%
4,781.30
5,023.90
-4.83%
EBITDA
2,023.10
1,938.50
4.36%
2,008.30
1,898.90
5.76%
2,062.10
941.20
119.09%
1,533.90
451.00
240.11%
EBIDTM
27.96%
28.55%
29.09%
29.99%
30.51%
17.99%
24.29%
8.24%
Other Income
216.20
58.70
268.31%
315.00
40.80
672.06%
174.00
853.90
-79.62%
138.50
121.90
13.62%
Interest
39.40
41.80
-5.74%
35.30
30.90
14.24%
37.10
34.70
6.92%
35.40
31.50
12.38%
Depreciation
373.50
323.70
15.38%
375.50
309.20
21.44%
353.30
301.80
17.06%
315.50
293.00
7.68%
PBT
1,826.40
1,631.70
11.93%
1,912.50
1,599.60
19.56%
1,845.70
1,458.60
26.54%
1,321.50
248.40
432.00%
Tax
448.20
393.80
13.81%
434.50
499.40
-13.00%
445.00
279.00
59.50%
369.00
161.90
127.92%
PAT
1,378.20
1,237.90
11.33%
1,478.00
1,100.20
34.34%
1,400.70
1,179.60
18.74%
952.50
86.50
1,001.16%
PATM
19.04%
18.23%
21.41%
17.38%
20.73%
22.54%
15.08%
1.58%
EPS
82.79
74.66
10.89%
88.86
66.96
32.71%
84.33
71.45
18.03%
57.63
5.83
888.51%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
27,212.50
24,669.70
21,545.20
19,047.50
17,517.00
15,448.20
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
Net Sales Growth
14.20%
14.50%
13.11%
8.74%
13.39%
8.17%
0.60%
-8.81%
3.63%
11.99%
 
Cost Of Goods Sold
8,014.70
7,657.70
7,442.20
6,078.90
5,554.40
4,494.80
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
Gross Profit
19,197.80
17,012.00
14,103.00
12,968.60
11,962.60
10,953.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
GP Margin
70.55%
68.96%
65.46%
68.09%
68.29%
70.90%
71.71%
73.96%
75.86%
74.80%
75.27%
Total Expenditure
19,585.10
18,320.70
17,777.80
15,177.60
15,046.60
12,270.00
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
Power & Fuel Cost
-
477.40
390.50
320.50
314.80
329.10
329.30
330.10
315.20
339.10
319.90
% Of Sales
-
1.94%
1.81%
1.68%
1.80%
2.13%
2.31%
2.33%
2.02%
2.26%
2.38%
Employee Cost
-
4,646.60
3,885.80
3,629.90
3,380.20
3,356.20
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
% Of Sales
-
18.84%
18.04%
19.06%
19.30%
21.73%
22.51%
21.88%
20.02%
19.60%
18.45%
Manufacturing Exp.
-
1,738.60
1,602.20
1,574.40
1,445.40
1,434.80
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
% Of Sales
-
7.05%
7.44%
8.27%
8.25%
9.29%
12.23%
13.29%
11.92%
13.31%
13.03%
General & Admin Exp.
-
1,497.50
1,547.60
1,251.80
1,195.20
1,132.10
1,193.40
1,339.90
1,271.40
1,037.30
1,004.30
% Of Sales
-
6.07%
7.18%
6.57%
6.82%
7.33%
8.36%
9.44%
8.17%
6.90%
7.49%
Selling & Distn. Exp.
-
1,989.40
1,919.20
1,567.70
1,408.30
1,423.50
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
% Of Sales
-
8.06%
8.91%
8.23%
8.04%
9.21%
9.31%
9.11%
7.59%
9.04%
9.43%
Miscellaneous Exp.
-
313.50
990.30
754.40
1,748.30
99.50
76.00
70.60
483.00
65.70
1,264.80
% Of Sales
-
1.27%
4.60%
3.96%
9.98%
0.64%
0.53%
0.50%
3.10%
0.44%
0.27%
EBITDA
7,627.40
6,349.00
3,767.40
3,869.90
2,470.40
3,178.20
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
EBITDA Margin
28.03%
25.74%
17.49%
20.32%
14.10%
20.57%
16.46%
17.41%
23.03%
23.25%
24.23%
Other Income
843.70
1,055.50
484.70
291.40
620.60
337.50
155.20
171.50
295.00
274.10
169.90
Interest
147.20
142.80
95.80
97.00
98.30
88.90
78.80
63.40
82.60
108.20
126.70
Depreciation
1,417.80
1,250.20
1,165.20
1,228.80
1,163.10
1,134.80
1,077.20
1,026.60
938.90
759.90
647.50
PBT
6,906.10
6,011.50
2,991.10
2,835.50
1,829.60
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
Tax
1,696.70
1,541.20
878.90
931.90
-140.30
385.80
438.00
296.50
751.10
563.20
683.10
Tax Rate
24.57%
25.64%
29.38%
32.87%
-7.67%
16.83%
32.43%
19.08%
26.27%
19.42%
25.81%
PAT
5,209.40
4,507.30
2,182.50
1,903.60
1,969.90
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
PAT before Minority Interest
5,209.40
4,507.30
2,182.50
1,903.60
1,969.90
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
19.14%
18.27%
10.13%
9.99%
11.25%
12.34%
6.39%
8.86%
13.54%
15.55%
14.63%
PAT Growth
44.54%
106.52%
14.65%
-3.37%
3.34%
108.92%
-27.43%
-40.35%
-9.79%
19.01%
 
EPS
368.94
319.21
154.57
134.82
139.51
135.00
64.62
89.04
149.27
165.47
139.04

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
23,286.10
19,212.40
17,641.70
15,598.80
14,023.60
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
Share Capital
83.30
83.20
83.20
83.10
83.00
83.00
82.90
85.30
85.20
85.10
Total Reserves
23,057.10
18,985.90
17,431.90
15,411.90
13,861.10
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
Non-Current Liabilities
-278.30
-508.30
-197.30
-807.50
2,113.00
2,538.40
456.10
876.70
1,678.40
2,182.30
Secured Loans
127.80
194.60
249.90
130.40
55.20
63.00
59.70
74.70
77.50
94.70
Unsecured Loans
0.00
380.00
380.00
0.00
2,144.80
2,445.90
485.20
993.80
1,354.00
1,980.80
Long Term Provisions
19.90
25.80
50.80
74.50
79.30
81.70
84.20
95.20
77.90
56.30
Current Liabilities
8,572.10
9,765.80
8,103.80
7,214.10
5,897.30
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
Trade Payables
2,268.40
2,266.20
1,810.90
1,524.80
1,367.10
1,334.50
1,056.90
906.80
867.30
893.20
Other Current Liabilities
4,697.90
3,660.60
3,338.10
3,512.00
2,820.70
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
Short Term Borrowings
739.00
2,708.20
2,314.50
1,653.20
1,212.50
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
Short Term Provisions
866.80
1,130.80
640.30
524.10
497.00
591.70
660.70
759.40
1,143.90
815.70
Total Liabilities
31,579.90
28,469.90
25,548.20
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
Net Block
9,219.10
8,121.50
8,205.70
6,850.30
7,191.00
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
Gross Block
25,567.10
23,096.40
21,886.70
19,335.50
18,048.40
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
Accumulated Depreciation
16,276.90
14,894.90
13,632.10
12,485.20
10,857.40
10,468.30
9,001.70
8,456.70
7,169.90
7,276.80
Non Current Assets
11,263.80
10,682.00
10,997.90
9,406.30
10,923.80
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
Capital Work in Progress
1,030.10
1,293.40
1,565.10
1,535.10
2,933.50
3,470.50
3,324.50
772.20
529.00
638.80
Non Current Investment
645.60
593.00
833.30
309.10
334.20
465.30
682.60
329.70
145.60
0.40
Long Term Loans & Adv.
355.90
451.70
377.00
688.70
426.70
564.80
482.10
290.40
418.10
232.20
Other Non Current Assets
13.10
222.40
16.80
23.10
38.40
36.80
34.50
44.30
6.40
0.00
Current Assets
20,316.10
17,787.90
14,550.30
12,599.10
11,110.10
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
Current Investments
4,340.20
2,022.90
1,378.50
2,368.70
2,252.90
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
Inventories
4,867.00
5,088.40
4,541.20
3,506.70
3,357.90
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
Sundry Debtors
7,248.50
6,676.40
4,964.10
5,027.80
3,986.90
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
Cash & Bank
1,730.20
2,419.20
2,078.80
205.30
222.80
263.80
386.50
492.10
1,872.40
2,300.60
Other Current Assets
2,130.20
736.90
865.00
1,046.10
1,289.60
1,440.00
1,218.70
1,115.60
1,231.00
1,214.60
Short Term Loans & Adv.
926.70
844.10
722.70
444.50
439.80
674.10
767.20
722.50
1,004.80
1,044.20
Net Current Assets
11,744.00
8,022.10
6,446.50
5,385.00
5,212.80
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
Total Assets
31,579.90
28,469.90
25,548.20
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
5,887.50
2,810.80
3,570.30
2,984.10
2,870.40
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
PBT
6,048.50
3,061.40
2,883.50
1,885.70
2,335.80
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
Adjustment
1,695.90
2,333.80
2,087.20
2,562.50
835.00
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
Changes in Working Capital
-785.50
-1,840.70
-828.80
-753.60
183.70
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
Cash after chg. in Working capital
6,958.90
3,554.50
4,141.90
3,694.60
3,354.50
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,071.40
-743.70
-571.60
-710.50
-484.10
-276.10
-577.00
-701.40
-546.40
-714.30
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,137.30
-2,638.70
-2,266.00
-492.30
-772.70
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
Net Fixed Assets
-1,438.50
-1,303.60
-2,618.10
-453.50
-275.60
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
Net Investments
-2,503.30
-287.50
836.30
-1,552.00
-297.00
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
Others
-195.50
-1,047.60
-484.20
1,513.20
-200.10
-270.50
-2,795.30
1,066.60
-380.80
-447.20
Cash from Financing Activity
-2,686.10
-242.20
-29.80
-2,515.90
-2,132.60
-444.00
-369.20
-1,700.10
-433.20
-24.20
Net Cash Inflow / Outflow
-935.90
-70.10
1,274.50
-24.10
-34.90
-129.30
-65.20
-476.90
-174.40
251.40
Opening Cash & Equivalents
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10
539.50
862.40
520.40
Closing Cash & Equivalent
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10
582.90
862.40

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
1388.98
1145.98
1052.59
932.31
840.01
752.35
734.72
731.49
572.92
457.33
ROA
15.01%
8.08%
8.01%
8.95%
8.66%
4.23%
6.14%
11.05%
13.67%
13.47%
ROE
21.36%
11.93%
11.53%
13.38%
14.42%
7.40%
10.20%
18.95%
26.63%
27.88%
ROCE
26.22%
14.59%
15.24%
10.81%
13.41%
8.21%
9.77%
19.55%
22.69%
24.77%
Fixed Asset Turnover
1.01
0.96
0.92
0.94
0.87
0.86
0.92
1.13
1.23
1.23
Receivable days
103.01
98.60
95.74
93.92
94.98
100.33
101.86
96.43
89.72
87.97
Inventory Days
73.65
81.57
77.11
71.52
74.03
73.63
69.56
60.11
60.27
62.06
Payable days
108.07
99.98
100.14
39.56
39.46
37.10
31.00
28.67
28.48
33.96
Cash Conversion Cycle
68.59
80.19
72.70
125.88
129.55
136.86
140.42
127.87
121.51
116.06
Total Debt/Equity
0.06
0.18
0.17
0.14
0.28
0.41
0.40
0.27
0.44
0.58
Interest Cover
43.36
32.96
30.23
19.61
26.78
18.14
25.51
35.61
27.80
21.89

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Dr. Reddy’s Laboratories’ arm to sell entire stake in Dr. Reddy’s Venezuela C.A., Venezuela
    15th Apr 2024, 09:50 AM

    Consequently, Dr. Reddy’s Venezuela C.A. will cease to be a wholly owned subsidiary of Dr. Reddy’s Swiss as well as step down wholly owned subsidiary of the Company

    Read More
  • Dr. Reddy’s launches drug-free migraine management wearable device Nerivio in Germany
    10th Apr 2024, 16:30 PM

    The launch marks the company’s entry into digital therapeutics in Europe

    Read More
  • Dr. Reddy's, Bayer sign marketing, distribution agreement for second brand of Vericiguat in India
    5th Apr 2024, 18:10 PM

    Vericiguat works on a pathway not currently targeted by existing heart failure treatments and can reduce the combined risk of cardiovascular death and heart failure hospitalization in such patient

    Read More
  • Dr. Reddy's Laboratories enters into exclusive partnership with Sanofi Healthcare India
    28th Mar 2024, 10:28 AM

    The company has entered into an exclusive partnership to promote and distribute their vaccine brands across private markets in India

    Read More
  • Dr. Reddy's Laboratories enters into license agreement with Pharmazz
    22nd Mar 2024, 16:46 PM

    As per the agreement, Dr. Reddy's has received exclusive rights to market and distribute Centhaquine in India

    Read More
  • Dr. Reddy’s Laboratories launches Versavo in United Kingdom
    19th Mar 2024, 14:51 PM

    Versavo is the first Dr. Reddy’s biosimilar product to be approved and launched in the UK

    Read More
  • Dr. Reddy's Laboratories incorporates wholly owned subsidiary
    15th Mar 2024, 12:00 PM

    The certificate of incorporation has been issued by the Ministry of Corporate Affairs, Government of India, on March 14, 2024

    Read More
  • Dr. Reddy's gets EIR from USFDA for formulations manufacturing facility in Hyderabad
    10th Feb 2024, 16:32 PM

    The USFDA has classified the inspection as Voluntary Action Indicated and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3)

    Read More
  • Dr.Reddy's Laboratories reports 11% rise in Q3 consolidated net profit
    31st Jan 2024, 14:19 PM

    Total consolidated income of the company increased by 8.83% at Rs 7453.00 crore for Q3FY24

    Read More
  • Dr. Reddy's Lab - Quarterly Results
    30th Jan 2024, 15:58 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.